pubmed-article:1332270 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:1332270 | lifeskim:mentions | umls-concept:C0042776 | lld:lifeskim |
pubmed-article:1332270 | lifeskim:mentions | umls-concept:C0014644 | lld:lifeskim |
pubmed-article:1332270 | lifeskim:mentions | umls-concept:C0006072 | lld:lifeskim |
pubmed-article:1332270 | lifeskim:mentions | umls-concept:C1333227 | lld:lifeskim |
pubmed-article:1332270 | lifeskim:mentions | umls-concept:C0599566 | lld:lifeskim |
pubmed-article:1332270 | lifeskim:mentions | umls-concept:C1998793 | lld:lifeskim |
pubmed-article:1332270 | lifeskim:mentions | umls-concept:C1880022 | lld:lifeskim |
pubmed-article:1332270 | pubmed:issue | 11 | lld:pubmed |
pubmed-article:1332270 | pubmed:dateCreated | 1992-12-1 | lld:pubmed |
pubmed-article:1332270 | pubmed:abstractText | Our initial results with a bovine papilloma virus (BPV) vector expression system indicated that we could produce significant amounts of Epstein-Barr virus (EBV) gp340/220 in the supernatant of a mouse fibroblast cell line. We have now extended these findings to show that the truncated version of gp340/220, where the membrane anchor sequence is deleted, is produced even after extended passage of the cells, at a level of approximately 1 mg/4 x 10(8) cells. A simple purification protocol using Sephacryl S300HR and gelatin agarose gives a product which is greater than 90% pure. This product is recognized by anti-gp340 monoclonal antibodies from five different epitope groups and induces antibody that recognizes the authentic gp340/220 and neutralizes EBV in vitro. The purified gp340/220 can be used in ELISA and stimulates the proliferation of T-cell clones specific for gp340/220. These characteristics, together with the fact that BPV-transformed lines have been utilized for the production of pharmaceuticals for use in humans, suggest that this gp340/220 is suitable as a source of antigen for vaccination to prevent EBV infection and related diseases. | lld:pubmed |
pubmed-article:1332270 | pubmed:language | eng | lld:pubmed |
pubmed-article:1332270 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1332270 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:1332270 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1332270 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1332270 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1332270 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1332270 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1332270 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:1332270 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:1332270 | pubmed:issn | 0264-410X | lld:pubmed |
pubmed-article:1332270 | pubmed:author | pubmed-author:ArrandJ RJR | lld:pubmed |
pubmed-article:1332270 | pubmed:author | pubmed-author:QualtiereL... | lld:pubmed |
pubmed-article:1332270 | pubmed:author | pubmed-author:MackettMM | lld:pubmed |
pubmed-article:1332270 | pubmed:author | pubmed-author:MadejMM | lld:pubmed |
pubmed-article:1332270 | pubmed:author | pubmed-author:MorganA JAJ | lld:pubmed |
pubmed-article:1332270 | pubmed:author | pubmed-author:ConwayM JMJ | lld:pubmed |
pubmed-article:1332270 | pubmed:author | pubmed-author:WallaceLL | lld:pubmed |
pubmed-article:1332270 | pubmed:author | pubmed-author:SweetJJ | lld:pubmed |
pubmed-article:1332270 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:1332270 | pubmed:volume | 10 | lld:pubmed |
pubmed-article:1332270 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:1332270 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:1332270 | pubmed:pagination | 777-82 | lld:pubmed |
pubmed-article:1332270 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:meshHeading | pubmed-meshheading:1332270-... | lld:pubmed |
pubmed-article:1332270 | pubmed:year | 1992 | lld:pubmed |
pubmed-article:1332270 | pubmed:articleTitle | Purification and characterization of Epstein-Barr virus gp340/220 produced by a bovine papillomavirus virus expression vector system. | lld:pubmed |
pubmed-article:1332270 | pubmed:affiliation | Department of Molecular Biology, Paterson Institute for Cancer Research, Manchester, UK. | lld:pubmed |
pubmed-article:1332270 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:1332270 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1332270 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1332270 | lld:pubmed |